Jazz Pharmaceuticals PLC (JAZZ) Financials

Jazz Pharmaceuticals PLC, a biopharmaceutical company, focuses on developing and commercializing medicines for the treatment of rare diseases and unmet medical needs. The company offers Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; and Defitelio, an injection for intravenous use for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation. It also develops Vyxeos, an intravenous chemotherapy for the treatment of adults with high-risk acute myeloid leukemia; and JZP-110, a late-stage investigational compound for the treatment of excessive sleepiness in patients with narcolepsy and other sleep disorders. In addition, the company sells psychiatry and other products, including Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; and Nizoral, an antifungal agent.

For the fiscal year ended December 31, 2019, Jazz Pharmaceuticals reported total revenue of $2.48 billion, a 14% increase compared to the previous year. The company's gross profit margin was 92.7%, reflecting its ability to generate high margins on its products. Jazz Pharmaceuticals also achieved strong profitability, with a net income of $517.4 million and earnings per share of $8.30. The company's balance sheet remained strong, with total assets of $9.89 billion and total liabilities of $4.31 billion. Jazz Pharmaceuticals had a strong cash position, with cash and cash equivalents totaling $1.65 billion, and a net debt of $3.30 billion. The company's stockholders' equity was $4.58 billion, indicating a healthy financial position. Jazz Pharmaceuticals generated positive cash flows from its operating activities, investing activities, and financing activities, resulting in a free cash flow of $526.9 million.

Looking ahead, Jazz Pharmaceuticals remains focused on its mission to bring innovative medicines to patients in need. The company continues to invest in research and development to drive future growth and expand its product portfolio. Jazz Pharmaceuticals aims to deliver long-term value for its investors while making a meaningful impact on the lives of patients. With its strong financial position and strategic focus, Jazz Pharmaceuticals is well-positioned for continued success in the biopharmaceutical industry.